Ctrl + Alt + Del – 2020
The world bemoans the ill-fated calamity of the CoVid outbreak, which has crippled the economy of the world, taken hundreds of thousands of human lives and relegated millions of people to the confines of their homes. There seems to be no end in sight. While most countries are trying their best to come to terms with the reality and find solutions to revive their economies, the greatest task at hand is finding a lasting medical solution.
Need for International Data Exchange
The pandemic nature of the outbreak has necessitated pharmaceutical translation for the exchange of research and information and for expediting clinical research. The need for is every more relevant considering that each country is at different phases of the outbreak and has unique data to share, which can benefit the rest of the world.
The Race against Time
The need to find medicines and vaccines is pressing. The economic cost of the standstill is heavy, and an extended lockdown has to find an alternative. Clinical trials are being expedited and government and non-government agencies are working in tandem to make things happen quicker, ending established protocols and norms. Medical translation of such data has gained ever more significance in this context.
Clinical Trials for Treatment Drugs
Pharmaceutical translation for clinical studies, trials and medical literature is essential for drugs that are being developed and rolled out for the treatment of CoVid-19. Some of the leading developments are the approvals for Favipiravir and Remdesivir.
Whereas Favipiravir is an oral medication meant for mild to moderate symptoms(https://en.wikipedia.org/wiki/Favipiravir), Remdesivir is an intravenous injection for treating more severe cases (https://www.pharmaceutical-technology.com/news/glenmark-favipiravir-covid-nod/).
Clinical Trials of Vaccines
There is immense optimism among the scientific fraternity about the development of a vaccine. More than a dozen Covid-19 vaccines are currently being tested globally in humans. The good news is that CoVid is curable, and hence the science for a vaccine is promising. Most vaccines are in varying stages of trials, and still several months from commercial use.
Among the more ambitious projects, the Oxford vaccine is expected to complete its third phase of clinical trials by September 2020. According to the Serum Institute of India, the vaccine is expected to hit the markets for commercial use by the end of this year.
https://www.tribuneindia.com/news/nation/oxford-vaccine-by-yr-end-partner-firm-107843
Another welcome news is that of the indigenous Indian vaccine named Covaxin is all set to undertake clinical trials on a fast track.
Bharat Biotech International partnered with ICMR to develop an indigenous vaccine for CoVid. There is news abuzz that they are targeting a commercial launch of the vaccine by the 15th August 2020! https://timesofindia.indiatimes.com/india/covid-19-icmrs-aug-15-deadline-to-vaccine-maker-stirs-a-row/articleshow/76778724.cms
Zydus Cadila have got an approval from the Drugs Controller General of India (DCGI) for human clinical trials too.
International Research and Pharmaceutical Translation
Scientific data is being shared across regional boundaries as a way to extend cooperation in a bid to curb the pandemic. Clinical tests in Japan, Korean and China need to be shared with anglophone and European scientists. Russian researchers need to cooperate with Indian scientists.
Japan, South-Korea, Singapore and Taiwan, who seemed to have effectively tackled the spread in the initial stages, are now going to suffer the onslaught when the rest of the world would have crossed the peak. On the other hand, Greece, Germany, Sweden and Norway have had immense success in Europe while Italy, the UK and Spain suffered a severe setback. In India, while Kerala, Karnataka and Telangana did well in containing the spread, Maharashtra and Delhi were badly affected. The scope of trials, treatment plans and success stories need to be transferred across regional and linguistic communities.
Pharmaceutical Translation at WordPar
During this difficult time, WordPar has been supporting pharmaceutical companies in translating their clinical research documents, e-learning modules and other documents. We have organised a team of specialised medical translators for ALL European, Indian and Asian languages. These translators have the necessary expertise to handle medical and pharmaceutical subjects.
For general information about our translation services please click: https://www.wordpar.com/translation-localization/. To get more details about our expertise in pharmaceutical translation, please read the article at https://www.wordpar.com/medical-pharmaceutical-translation/. Read more about our e-learning localization for medical products here: https://www.wordpar.com/e-learning-localization/.
Medical Interpretation
Social distancing and quarantine norms have added another dimension to the need for remote interpreting. At the same time, the need for medical consultation is increasing too. The requirement for medical interpretation has seen a multi-fold increase during these times. Consumer and marketing research are areas where remote interpretation has increased. Many industries are trying to assess the impact of CoVid on consumer behaviour and are conducting surveys involving remote interpretation.
Technologies such as Skype and Zoom have given an impetus to remote conference interpretation in the medical field. More information about medical interpreting can be read on https://www.wordpar.com/interpretation/.
Reach our Medical Translator Team
For support in pharmaceutical translations in USA and Canada, please mail us at info@wordpar.ca.
For assistance in medical translation in Europe and India, please mail us at info@wordpar.com.
Support for medical research translation for the rest of the world can be requested by writing to admin@wordpar.ca.
We are hopeful and pray that the pandemic will end soon, and we will all return to our normal way of life.
The post Pharmaceutical Translation in the CoVid-19 Context appeared first on Wordpar.